SEARCH

SEARCH BY CITATION

References

  • 1
    Soloway MS,Martino C. Prophylaxis of bladder tumor implantation. Intravesical and systemic chemotherapy. Urology. 1976; 7: 29-34.
  • 2
    Soloway MS,Masters S. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer. 1980; 46: 1158-1163.
  • 3
    Sylvester RJ,Oosterlinck W,van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004; 171(6 pt 1): 2186-2190, quiz 2435.
  • 4
    Weldon TE,Soloway MS. Susceptibility of urothelium to neoplastic cellular implantation. Urology. 1975; 5: 824-827.
  • 5
    Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumors, 6th ed. New York, NY: John Wiley & Sons; 2002.
  • 6
    Hall MC,Chang SS,Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007; 178: 2314-2330.
  • 7
    Lotan Y,Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the follow-up of patients with transitional cell carcinoma of the bladder: a decision analytical approach. J Urol. 2002; 167: 75-79.
  • 8
    Berrum-Svennung I,Granfors T,Jahnson S,Boman H,Holmang S. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol. 2008; 179: 101-105; discussion 105-106.
  • 9
    Tolley DA,Parmar MK,Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996; 155: 1233-1238.
  • 10
    Ali-el-Dein B,Nabeeh A,el-Baz M,Shamaa S,Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol. 1997; 79: 731-735.
  • 11
    Bouffioux C,Kurth KH,Bono A, et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 1995; 153(3 pt 2): 934-941.
  • 12
    Oosterlinck W,Solsona E,Akaza H, et al. Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology. 2005; 66( 6 suppl 1): 75-89.
  • 13
    Donat SM,North A,Dalbagni G,Herr HW. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol. 2004; 171(2 pt 1): 636-639.
  • 14
    Soloway MS,Bruck DS,Kim SS. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol. 2003; 170(2 pt 1): 438-441.
  • 15
    Okamura K,Ono Y,Kinukawa T, et al. Randomized study of single early instillation of (2′′R)-4′-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer. 2002; 94: 2363-2368.
  • 16
    [No authors listed]. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer. Br J Urol. 1985; 57: 680-685.
  • 17
    [No authors listed]. The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Br J Urol. 1994; 73: 632-638.
  • 18
    Oosterlinck W,Kurth KH,Schroder F,Bultinck J,Hammond B,Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol. 1993; 149: 749-752.
  • 19
    Rajala P,Kaasinen E,Raitanen M,Liukkonen T,Rintala E. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study—FinnBladder III long-term results. J Urol. 2002; 168: 981-985.
  • 20
    Rajala P,Liukkonen T,Raitanen M, et al. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study—FinnBladder III. J Urol. 1999; 161: 1133-1135; discussion 1135-1136.
  • 21
    Solsona E,Iborra I,Ricos JV,Monros JL,Casanova J,Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up. J Urol. 1999; 161: 1120-1123.
  • 22
    Tolley DA,Hargreave TB,Smith PH, et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). BMJ (Clin Res Ed). 1988; 296: 1759-1761.
  • 23
    Brassell SA,Kamat AM. Contemporary intravesical treatment options for urothelial carcinoma of the bladder. J Natl Compr Canc Netw. 2006; 4: 1027-1036.
  • 24
    Shapiro O,Jones K,Wang C,Landas S,Haas GP. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection. Can J Urol. 2006; 13: 3317-3320.
  • 25
    O'Donnell MA. Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am. 2005; 32: 121-131.
  • 26
    Cai T,Nesi G,Tinacci G, et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol. 2008; 180: 110-115.
  • 27
    Cliff AM,Romaniuk CS,Parr NJ. Perivesical inflammation after early mitomycin C instillation. BJU Int. 2000; 85: 556-557.
  • 28
    Nieuwenhuijzen JA,Bex A,Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol. 2003; 43: 711-712.
  • 29
    Oddens JR,van der Meijden AP,Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol. 2004; 46: 336-338.
  • 30
    Doherty AP,Trendell-Smith N,Stirling R,Rogers H,Bellringer J. Perivesical fat necrosis after adjuvant intravesical chemotherapy. BJU Int. 1999; 83: 420-423.
  • 31
    Koya MP,Simon MA,Soloway MS. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol. 2006; 175: 2004-2010.
  • 32
    Liu CC,Chou YH,Huang CH,Tsai KB. Bladder wall calcification after intravesical chemotherapy with mitomycin C—a case report. Kaohsiung J Med Sci. 2001; 17: 274-277.